Results 101 to 110 of about 21,457 (213)

Abatacept blocks anti-citrullinated protein antibody and rheumatoid factor mediated cytokine production in human macrophages in IDO-dependent manner

Arthritis Research & Therapy, 2018
Background The anti-inflammatory effect of abatacept is most pronounced in patients with high-titer autoantibodies (including anticitrullinated protein antibodies [ACPA] and rheumatoid factor [RF]).
Aline Bozec, Yubin Luo, Cecilia Engdahl, Camille Figueiredo, Holger Bang, Georg Schett   +5 more
doaj   +1 more source

The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation

, 2016
Background: Juvenile idiopathic arthritis (JIA) is characterised by joint pain, swelling and limitation of movement caused by inflammation. Subsequent joint damage can lead to disability and growth restriction.
Abbvie, Albarouni, All Wales Medicines Strategy Group, All Wales Medicines Strategy Group, All Wales Medicines Strategy Group, All Wales Medicines Strategy Group, Angeles-Han, Arthritis Care, Arthritis Care, Arthritis Care, Arthritis Care, Arthritis Research UK, Baildam, Baildam, Barton, Baszis, Bechtold, Berard, Bertilsson, Briggs, Briggs, Bristol-Myers Squibb, British Society for Paediatric and Adolescent Rheumatology, British Society for Paediatric and Adolescent Rheumatology, Brodszky, Brunner, Brunner, Brunner, Brunner, Brunner, Bruns, Bucher, Burgos-Vargas, Burgos-Vargas, Burgos-Vargas, Burgos-Vargas, Burgos-Vargas, Burgos-Vargas, Canadian Agency for Drugs and Technologies in Health, Chang, Chen, Connock, Consolaro, Consolaro, Consolaro, Consolaro, Cordero-Coma, Costa, Cummins, Cummins, Curtis, Dakin, De Benedetti, De Benedetti, Department of Health, Dias, Diaz-Llopis, Donegan, Drummond, Duffy, European Medicines Agency, European Medicines Agency, European Medicines Agency, European Medicines Agency, Feeny, Foeldvari, Gani, Garcia-De-Vicuna, Geikowski, Giannini, Glenny, Haapasaari, Heiligenhaus, Hendry, Higgins, Higgins, Horizon Scanning Centre, Horneff, Horneff, Imagawa, Joint Formulary Committee, Kearsley-Fleet, Kearsley-Fleet, Kemper, Khan, Kingsbury, Klein, Kuhlthau, Lloyd Jones, Lovell, Lovell, Lovell, Lovell, Lovell, Lovell, Lovell, Lovell, Luca, Luca, Lundkvist, Magli, Malottki, Martin, McErlane, McErlane, Mills, Minden, Minden, Monthly Index of Medical Specialties, Moorthy, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Rheumatoid Arthritis Society, National Rheumatoid Arthritis Society (NRAS), NHS England Clinical Reference Group for Paediatric Medicine, NHS England Specialised Services Clinical Reference Group for Specialised Ophthalmology, Nikolakopoulou, Office for National Statistics, Otten, Otten, Packham, Paediatric Formulary Committee, Parsons, Pennington, Petty, Pfizer Ltd, Philips, Prakken, Prince, Prince, Prince, Prince, Ramanan, Ravelli, Ravelli, Reeves, Riemsma, Rigante, Roche, Ruperto, Ruperto, Ruperto, Ruperto, Ruperto, Ruperto, Ruperto, Simonini, Simonini, Simpson, Simpson, Simpson, Smith, Sonnenberg, Stagi, Stevenson, Thierry, Thomson, Thornton, Tong, Tse, Tynjala, Ungar, Ungar, Vidqvist, Wallace, Wallace, Wallace, Yagudina, Zannin, Zeng   +171 more
core   +1 more source

Asian Pacific Association of Gastroenterology (APAGE) Clinical Practice Guidelines on the Use of Small Molecules and IL‐23 p19 Inhibitors in Ulcerative Colitis and Crohn's Disease

Journal of Gastroenterology and Hepatology, EarlyView.
ABSTRACT Ulcerative colitis (UC) and Crohn's disease (CD) are increasingly prevalent in the Asia Pacific region, necessitating updated, region‐specific guidance on advanced therapies. Targeted small molecule agents, such as filgotinib, tofacitinib, upadacitinib, etrasimod, and ozanimod; and the IL‐23 p19 inhibitors (guselkumab, mirikizumab ...
Choon Jin Ooi, Khoon Lin Ling, Julajak Limsrivilai, Shu‐Chen Wei, Joyce Wing Yan Mak, Taku Kobayashi, Luan Minh Dang, Rupert W. Leong, Huiyu Lin, Meng‐Tzu Weng, Wan Chee Ong, Vineet Ahuja, Satimai Aniwan, Ryota Hokari, Wei Jie Jonathan Lee, Alex Hwong‐Ruey Leow, Wai‐Keung Leung, Wee‐Chian Lim, Govind Makharia, Katsuyoshi Matsuoka, Nazri Mustaffa, Siew‐Chien Ng, Mathew Philip, Pises Pisespongsa, Raja Affendi Raja Ali, Zhi Hua Ran, Marcellus Simadibrata, Jose Sollano, Malcolm Tan, Hang Dao Viet, Nik Razima Wan Ibrahim, Kai Chun Wu, Byong Duk Ye, Ida Hilmi, Asian Pacific Association of Gastroenterology (APAGE) Inflammatory Bowel Disease Committee and Asian Education Network in IBD (AEN‐IBD)   +34 more
wiley   +1 more source

Comparative clinical utility of once-weekly subcutaneous abatacept in the management of rheumatoid arthritis

Therapeutics and Clinical Risk Management, 2014
Chadi Rakieh, Philip G ConaghanLeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, UKAbstract: Biologic therapies in rheumatoid arthritis are now part of standard ...
Rakieh C, Conaghan PG
doaj  

Comparative effectiveness of abatacept versus TNF inhibitors in rheumatoid arthritis patients who are ACPA and shared epitope positive

Advances in Rheumatology
Background The HLA-DRB1 shared epitope (SE) is a risk factor for the development of rheumatoid arthritis (RA) and the production of anti-citrullinated protein antibodies (ACPAs) in RA patients. Our objective was to examine the real-world effectiveness of
Leslie R. Harrold, Keith Wittstock, Sheila Kelly, Xue Han, Joe Zhuo, Amy Schrader, Nicole Middaugh, Page C. Moore, Vadim Khaychuk   +8 more
doaj   +1 more source

Laser Acupuncture on the Management of Xerostomia in Sjögren's Disease: A Randomized Clinical Trial

Oral Diseases, EarlyView.
ABSTRACT Objectives This study evaluated the efficacy of photobiomodulation (PBM) at acupuncture points for managing xerostomia in patients with Sjögren's Disease. Material and Methods In this randomized, double‐blind clinical trial, 50 patients were assigned to PBM group (n = 22) or sham‐PBM group (n = 28).
Matheus Ferreira Linares, Tainá Duarte dos Santos França, Maria Clara Barros Madureira Ferreira, Michele Gomes do Nascimento, Angela Luzia Branco Pinto Duarte, Luiz Alcino Gueiros   +5 more
wiley   +1 more source

Abatacept reduces levels of switched memory B cells, autoantobodies, and immunoglobulins in patients with Rheumatoid Arthritis [PDF]

, 2014
Objective. Abatacept (ABA) is a chimeric molecule, able to block the CD28-mediated costimulatory pathway. To evaluate the hypothesis that, through this mechanism of action, ABA may down-modulate the immune responses of B lymphocytes in rheumatoid ...
A.PEDRINI, A.TINCANI, D.RICOTTA, L.CAIMI, L.PAOLINI, M.SCARSI, P.AIRO’, S.PIANTONI   +7 more
core  

Fatal Chronic Varicella‐Zoster Viral Infection in a Young Man With Chediak–Higashi Syndrome

Pediatric Dermatology, EarlyView.
ABSTRACT Chediak–Higashi syndrome (CHS) is a rare autosomal recessive primary immunodeficiency characterized by partial oculocutaneous albinism, neurologic involvement, and a predisposition to severe infections. Patients are particularly susceptible to developing hemophagocytic lymphohistiocytosis (HLH), which significantly worsens prognosis. We report
Albane Badet, Clément Pruvot, Zoé Manssens, Wadih Abou‐Chahla, Sébastien Buche   +4 more
wiley   +1 more source

Cost-effectiveness modelling of biological treatment sequences in moderate to severe rheumatoid arthritis in France [PDF]

, 2017
Objectives. Modern treatment of RA includes the use of biologics. Their cost is high and comparison between different treatment strategies is needed. Method. Direct medical costs of RA in France were evaluated based on expert opinion.
Beresniak, Ariel, Boccard, Eric, Bregman, Bruno, Dupont, Danielle, Gossec, Laure, Goupille, Philippe, Saraux, Alain   +6 more
core  

Janus Kinase Inhibitors for the Treatment of Pediatric Morphea: A Systematic Review

Pediatric Dermatology, EarlyView.
ABSTRACT Morphea, also known as localized scleroderma (LoS), is an inflammatory, fibrosing dermatologic disorder of the skin and underlying tissues with associated comorbidities including joint contractures, limb‐length discrepancies, and inflammatory arthropathy occurring more commonly in children.
Alexa Moschella, Celina DeBiasio, Carmen Liy‐Wong   +2 more
wiley   +1 more source